PDF(Pubmed)
Abstract：
The field of cardio-oncology was born from the necessity for recognition and management of cardiovascular diseases among patients with cancer. This need for this specialty continues to grow as patients with cancer live longer as a result of lifesaving targeted and immunologic cancer therapies beyond the usual chemotherapy and/or radiation therapy. Often, potentially cardiotoxic anticancer treatment is necessary in patients with baseline cardiovascular disease. Moreover, patients may need to continue therapy in the setting of incident cancer therapy-associated cardiotoxicity. Herein, we present and discuss the concept of permissive cardiotoxicity as a novel term that represents an essential concept in the field of cardio-oncology and among practicing cardio-oncology specialists. It emphasizes a proactive rather than reactive approach to continuation of lifesaving cancer therapies in order to achieve the best oncologic outcome while mitigating associated and potentially off-target cardiotoxicities.
摘要：
心脏肿瘤学领域源于癌症患者对心血管疾病的识别和管理的必要性。随着癌症患者的寿命延长，这种特殊的需求持续增长，因为除了常规的化学疗法和/或放射疗法之外，有针对性的和免疫癌症疗法可以挽救生命。通常,在基线心血管疾病患者中,潜在的心脏毒性抗癌治疗是必要的.此外，在偶发癌症治疗相关心脏毒性的情况下,患者可能需要继续治疗.在这里，我们提出并讨论了许可性心脏毒性的概念，这是一个新术语，代表了心脏肿瘤学领域和执业心脏肿瘤学专家的基本概念。它强调主动而不是反应性的方法来继续挽救生命的癌症治疗，以达到最佳的肿瘤结果，同时减轻相关的和潜在的脱靶心脏毒性。
